Hematology / Oncology
Osimertinib,40mg – Osimertinib,80mg
Osiem (Osimertinib ，previously known as AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug used for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutationpositive non-small cell lung cancer (NSCLC) .
Emlutini (Ibrutinib) is a small molecule drug that binds permanently to a protein, Bruton’s tyrosine kinase (BTK), that is important in B cells; the drug is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, Waldenström’s macroglobulinemia, and Marginal zone lymphoma，a form of non-Hodgkin’s lymphoma.
Palbociclib, 75mg – Palbociclib, 100mg – Palbociclib, 125mg
Palbociclib (Palbociclib) is a drug for the treatment of ER-positive and HER2-negative advanced or metastatic breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
Soranni (Sorafenib) is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), and radioactive iodine resistant advanced thyroid carcinoma.
Abyrone(abiraterone) is a synthetic, steroidal CYP17A1 inhibitor and the active metabolite of abiraterone acetate, an ester and prodrug of abiraterone that is used in the treatment of prostate cancer.
Lenalidomide 2.5mg, 5mg, 10mg, 25mg
lenalidomide is a prescription medicine approved in combination with dexamethasone to treat patients with multiple myeloma (a type of cancer of the bone marrow) who already have had prior therapy. It is also approved to treat certain patients who have certain types of myelodysplastic syndromes (a group of conditions in which the bone marrow does not produce enough mature blood cells).